Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 4Lymphoid 2Gynecologic 1

Conditions

Lymphoma 2

Interventions

Rituximab 377Cyclophosphamide 180Bendamustine Hydrochloride 110obinutuzumab 100Vincristine 95fludarabine 92Prednisone 90Doxorubicin 90ibrutinib 89venetoclax 86Lenalidomide 82Gemcitabine 65acalabrutinib 48Brentuximab Vedotin 44pembrolizumab 43zanubrutinib 41Dexamethasone 41idelalisib 37ofatumumab 32Oxaliplatin 30Chlorambucil 29polatuzumab vedotin 25blinatumomab 25tocilizumab 24Azacitidine 24Prednisolone 23tositumomab I-131 22tisagenlecleucel 21glofitamab 21Nivolumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × VTX-2337 × Lymphoid × Clear all
NCT00688415 2019-09-25

Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer

Celgene

Phase 1 Completed
33 enrolled
Lymphoid

Lymphoma

NCT01289210 2019-09-25

VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas

Celgene

Phase 1/2 Terminated
2 enrolled 4 charts
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡